Hongzi Chen

955 total citations · 1 hit paper
7 papers, 788 citations indexed

About

Hongzi Chen is a scholar working on Molecular Biology, Surgery and Epidemiology. According to data from OpenAlex, Hongzi Chen has authored 7 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Surgery and 3 papers in Epidemiology. Recurrent topics in Hongzi Chen's work include Peroxisome Proliferator-Activated Receptors (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Urinary Tract Infections Management (2 papers). Hongzi Chen is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Urinary Tract Infections Management (2 papers). Hongzi Chen collaborates with scholars based in United States, Germany and United Kingdom. Hongzi Chen's co-authors include Wayde M. Weston, Ken Williams, Andrew S. Greenberg, Steven M. Haffner, Martin I. Freed, Alexander R. Cobitz, Jean‐Paul Albertini, Dahong Yu, P. Valensi and Barry J. Goldstein and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Hongzi Chen

7 papers receiving 749 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

2002 727 citations Steven M. Haffner, Andrew S. Greenberg et al. Circulation profile →

Peers

Hongzi Chen

MB

EDM

EPIDE

CCM

SURGE

Charles D. Meyers United States

José C. Sandoval Japan

Katja Fuecker Germany

Taichi Sugizaki Japan

Panai Song China

Laura Agostinelli Italy

Heidrun Mehling Germany

Alexandros Sachinidis Greece

Emilia Ip Australia

Feruze Yılmaz Enç Türkiye

Charles D. Meyers United States

Hongzi Chen

240 ×0.6

MB

375 ×1.0

EDM

125 ×0.5

EPIDE

159 ×0.9

CCM

296 ×1.9

SURGE

Citations per year, relative to Hongzi Chen Hongzi Chen (= 1×) peers Charles D. Meyers

Countries citing papers authored by Hongzi Chen

Since Specialization

Citations

This map shows the geographic impact of Hongzi Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongzi Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongzi Chen more than expected).

Fields of papers citing papers by Hongzi Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongzi Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongzi Chen. The network helps show where Hongzi Chen may publish in the future.

Co-authorship network of co-authors of Hongzi Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Hongzi Chen. A scholar is included among the top collaborators of Hongzi Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongzi Chen. Hongzi Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Moeck, Greg, Leanne B. Gasink, Rodrigo E. Mendes, et al.. (2024). Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial Agents and Chemotherapy. 68(7). e0023624–e0023624. 10 indexed citations

2.

Moeck, Greg, Leanne B. Gasink, Marcus Dörr, et al.. (2023). 2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study. Open Forum Infectious Diseases. 10(Supplement_2). 2 indexed citations

3.

Albertini, Jean‐Paul, et al.. (2007). Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis. 195(1). e159–e166. 17 indexed citations

4.

Yu, Dahong, Susan J. Murdoch, Shamik Parikh, et al.. (2006). Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diabetes and Vascular Disease Research. 3(3). 189–196. 17 indexed citations

5.

Brunzell, John D., Santica Marcovina, Dahong Yu, et al.. (2004). 1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. Journal of the American College of Cardiology. 43(5). A504–A504. 4 indexed citations

6.

Goldstein, Barry J., et al.. (2003). Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?. Current Medical Research and Opinion. 19(3). 192–199. 11 indexed citations

7.

Haffner, Steven M., Andrew S. Greenberg, Wayde M. Weston, et al.. (2002). Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation. 106(6). 679–684. 727 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact